相关实验视频

Updated: Jun 22, 2025

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging

Published on: October 20, 2017

向粉样蛋白质用于神经退行性疾病的临床诊断

Shenqing Zhang^1,2, Hui Dong^3,4, Jiang Bian^1,2

¹Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, China.

Fundamental research

|June 27, 2024

概括

针对异常的粉样蛋白聚合是诊断神经退行性疾病 (NDs) 的关键. 本综述探讨了正子发射断层扫描 (PET) 扫描和后翻译修饰 (PTM) 生物标志物,以改善ND诊断.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
医学诊断医学诊断医学诊断

背景情况:

粉样蛋白 (粉样β,tau,α-synuclein) 的异常聚合是神经退行性疾病 (NDs) 的标志,如阿尔茨海默病 (AD) 和帕金森病 (PD).
这些粉样蛋白的翻译后修饰 (PTM) 在疾病进展过程中发生变化,提供潜在的诊断见解.

研究的目的:

审查目前针对神经退行性疾病中的粉样聚合物的策略.
专注于使用正子发射断层扫描 (PET) 和后翻译修饰 (PTM) 生物标志物的阿尔茨海默病诊断应用.

主要方法:

总结了用于检测大脑中的粉样纤维的小分子PET标记物的发展.
讨论在脑脊液和血中检测PTM生物标志物的临床诊断.

主要成果:

审查了针对粉样蛋白聚合物的两个主要策略:PET成像和PTM生物标志物检测.
该审查强调了PTMs的病理作用及其在诊断神经退行性疾病中的实用性.

结论:

包括PET扫描和PTM分析在内的粉样蛋白向策略对神经退行性疾病的分子诊断有前途.
未来的方向可能涉及结合多种策略来克服技术挑战并提高诊断准确性.

关键词:

阿尔茨海默氏症的疾病是阿尔茨海默氏症.粉样蛋白聚合物的聚合.生物标志物生物标志物临床诊断临床诊断临床诊断神经退行性疾病的神经退行性疾病定子发射断层扫描 (PET) 追踪器后翻译修改后的修改.塔乌·塔乌 (Tau Tau) 是一个

更多相关视频

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Amyloid Fibrils

Amyloid Fibrils